TITLE

Oncolytics Biotech Trial Reports Positive Results

PUB. DATE
August 2011
SOURCE
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses the preliminary results reported by Oncolytics Biotech Inc. regarding the Phase 2 clinical trials of its REOLYSIN as of August 2011. Oncolytics is a Canadian-based firm and its new drug, taken intravenously with paclitaxel and carboplatin, showed promising results in its treatment of lung cancer. This announcement was made at the International Association for the Study of Lung Caner World Conference on Lung Cancer. A technical description of the results is offered.
ACCESSION #
63617959

 

Related Articles

  • Oncolytics' First Phase II Data: Another Winner in Melanoma? Osborne, Randy // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p1 

    The article offers information on the Phase II study by Oncolytics Biotech Inc. with its Reolysin in metastatic melanoma which met the primary endpoint, with 14 patients achieving partial response (PR) for a 71.5 percent disease control rate. The positive report follows the promising 85.7...

  • ONCOLYTICS ENROLLED FOR PHASE I DELIVERY OF REOLYSIN.  // Worldwide Biotech;Oct2006, Vol. 18 Issue 10, p7 

    The article reports on the completion of patient enrollment by Oncolytics Biotech Inc. for the Phase I U.S. clinical trial investigating the systemic delivery of Reolysin to patients with advanced cancers in 2006. It reveals the number of patients who were treated in the Phase I trial with...

  • From the Bedside to the Bedside.'.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p7 

    This article deals with the updated results obtained by Oncolytics Biotech Inc. from a Phase I/II trial of Reolysin in Great Britain. According to the study, the drug was well tolerated in patients with advanced cancers when combined paclitaxel/carboplatin. A total clinical benefit rate of 74%...

  • Clinic Roundup.  // BioWorld Today;4/3/2012, Vol. 23 Issue 64, p7 

    This section offers news briefs on clinical trials. Nektar Therapeutics Inc. has dosed the first subjects in the Phase I trial of a short-acting mu-opioid analgesic candidate. Patient enrollment was completed by Oncolytics Biotech Inc. for the first stage of its Phase III trial of Reolysin in...

  • CLINIC ROUNDUP.  // BioWorld Today;5/12/2008, Vol. 19 Issue 92, p2 

    This section offers news briefs concerning clinical trials. The accrual time for the Phase III study of the investigational chemosensitizing drug phenoxodiol called Ovarian Tumor Response (OVATURE) has been lengthened by Marshall Edwards Inc. Enrollment of patients for a trial of intravenous...

  • Oncolytics' Phase III Borrows Adaptive Design in SPA Trial. Hollingsworth, Catherine // BioWorld Today;10/5/2009, Vol. 20 Issue 191, p1 

    The article reports that the drug Reolysin by Oncolytics Biotech Inc. is being studied for the treatment of head and neck cancer. The trial will test the intravenous administration of Reolysin with the chemotherapy combination of paclitaxel and carboplatin as against chemotherapy alone. The...

  • CLINIC ROUNDUP.  // BioWorld Today;5/27/2010, Vol. 21 Issue 102, p5 

    This section offers news briefs concerning clinical trials, including the enrollment in a Phase IIb trial to be conducted by EpiCept Corp., the completion of the enrollment in the Phase IIA proof-of-concept trial of Aganocide by NovaBay Pharmaceuticals Inc. and a patient enrollment by Oncolytics...

  • CLINIC ROUNDUP.  // BioWorld Today;4/26/2010, Vol. 21 Issue 79, p2 

    This section offers news briefs on clinical trials including the start of a Phase II trial by Affiris AG for its Alzheimer's disease vaccine candidate and completion by Oncolytics Biotech Inc. of Phase I enrollment in its trial of Reolysin in patients with recurrent malignant gliomas.

  • CLINIC ROUNDUP.  // BioWorld Today;6/23/2008, Vol. 19 Issue 121, p8 

    This section offers news briefs concerning the biopharmaceutical industry. The Phase II trial of intravenous Reolysin in combination with paclitaxel and carboplatin was launched by Oncolytics Biotech Inc. A deal was made by Pharmaxis Ltd. with the U.S. Food and Drug Administration (FDA) for a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics